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Abstract  
Objective: 23% of mesothelioma tumor specimens have a mutation 
in the BRCA1-associated protein 1 (BAP1) gene and germline BAP1 
mutations predispose to malignant pleural mesothelioma (MPM). Our 
aim was to investigate germline BAP1 mutations in sporadic MPM 
patients. 
Materials and Methods: Exonic DNA from peripheral blood 
leucocytes of 78 MPM patients was screened for germline BAP1 
mutation. 
Results: One out of 78 patients showed a germline synonymous 
mutation in exon 11. In all other patients wild-type sequence without 
any single-nucleotide polymorphisms was detected. 
Conclusions: Taking into account previous similar screenings, the 
prevalence of germline BAP1 mutations in sporadic MPM patients 
can be estimated around 1-2%, suggesting a minor role of germline 
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1. Introduction  
Malignant pleural mesothelioma (MPM) is a rare cancer that 
originates from the pleural lining and that has a strong association to 
asbestos. The prognosis and the treatment options at the moment 
are very poor with a patient median survival time of less than 12 
months after diagnosis [1]. To develop more effective MPM-specific 
therapeutics, much effort has been put into the investigation of 
cancer genes driving MPM oncogenesis. Besides the two most 
abundant alterations in MPM concerning cyclin-dependent kinase 
inhibitor 2A (CDKN2A) and neurofibromatosis 2 (NF2) genes, 
recently genetic alterations in the BAP1 (BRCA1-associated protein 
1) gene, which is localized on chromosome 3 (3p21.1), have been 
identified in 23% of MPM specimens [2].  
BAP1 was initially identified in lung cancer cell lines as a protein that 
binds to BRCA1 [3]. It is a 90 kDa nuclear-localised deubiquitinating 
enzyme with ubiquitin carboxyl hydrolase (UCH) activity; and it is the 
only member of the UCH family with two nuclear localisation signal 
(NLS) motifs [4]. BAP1-mediated tumour suppression requires both 
deubiquitinating activity and nuclear localisation of BAP1 [4]. BRCA1 
does not seem to be necessary for the tumor suppressor activity of 
BAP1 [4] and it is not a substrate of BAP1 [5]. However, BAP1 is part 
of essential cell cycle regulators[6] and probably associated with 
regulation of transcription [7]. BAP1 binds and deubiquitinates the 
transcriptional regulator host cell factor 1 (HCF-1), which interacts 
with histone-modifying complexes [8, 9]. Together, these data 
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indicate a complex mode of action for BAP1 involving different 
cellular pathways. It is even hypothesized that BAP1 effects can vary 
in different cell types and/or species [10]. BAP1 was shown to fulfill 
criteria of a genuine tumor suppressor gene, which presumably 
becomes apparent after a two-step inactivation according Knudson’s 
two-hit model [4, 9, 11]: one allele of BAP1 being inactivated via 
inherited mutation (or monosomy of chromosome 3 [12]); and the 
remaining allele being lost by somatic BAP mutation(s) leading to 
biallelic inactivation [9, 13]. 
Sporadic BAP1 mutation have been described in uveal melanoma, 
cutaneous melanoma and other melanocytic tumors, renal cell 
carcinoma and other cancers [9]. Besides the common sporadic 
BAP1 mutations, germline BAP1 mutations have been detected in 
families with a high incidence of MPM [14]. Individuals with 
heterozygous BAP1 germline mutations are affected by a newfound 
tumor predisposition syndrome characterized by very high risk of 
developing MPM, uveal melanoma (UV), cutaneous melanoma, 
atypical melanocytic benign neoplasms [15, 16] and different cancer 
types, such as lung adenocarcinoma, meningioma [17], and renal cell 
carcinoma [18] (http://omim.org/entry/614327). 
To date only two studies [13, 14] investigated the frequency of this 
germline mutation in 26 and 9 sporadic MPM  patients, respectively, 
and found a prevalence of 8% and 0%, respectively. In this study, we 
present the largest screening to date of germline BAP1 mutation in 
sporadic MPM patients. 
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2. Materials and Methods  
2.1. Patient blood samples 
78 blood samples were obtained from patients of a multicenter 
clinical study (SAKK 17/04, NCT00334594, unpublished) with 
pathologically proven diagnosis of MPM and after written informed 
consent. Blood samples were obtained between 2008 and 2012. 
Staging was based on the IMIG classification [19] selecting the 
lowest stage in case of ambiguous results. In SAKK17/04 trial only 
patients diagnosed with stage I, II or III MPM were included. The 
study was approved by the Ethics Committee of the University 
Hospital Zürich. Clinical records were reviewed to document the 
patient’s sex, age and stage and histology of malignant pleural 
mesothelioma. 
Peripheral whole blood was collected by needle venipuncture in 
serum tubes. Total DNA was purified according to the protocol of 
Qiagen DNeasy® Blood & Tissue Kit.  
2.2. PCR and Analysis 
PCR of different fragments was performed for unreported samples to 
define optimal PCR conditions. Products were confirmed by 
electrophoresis on a 2% agarose gel and excised. After purification 
according to the Macherey-Nagel NucleoSpin® Gel and PCR Clean-
up protocol products were send for Sanger sequencing (done by 
Microsynth AG, Balgach, Switzerland). 
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Then eleven PCR fragments that encompassed the entire BAP1 
coding exons and adjacent intron regions were amplified for all 
samples including a positive control (cell lines H2452 and H28). 
Primers and conditions used are listed in Supplementary Table I. 
PCR product clean up and high-throughput sequencing was done by 
Microsynth AG (Balgach, Switzerland). 
Sequencing results were analyzed with CLC Main Workbench 
(Version 6.1.1, CLCbio, Aarhus, Denmark) using NCBI Sequence: 
NG_031859.1 as reference. 
We used variation data observed in 413 exomes from the CoLaus 
cohort [20], which were sequenced at the Wellcome Trust Sanger 
Institute (WTSI) as part of a partnership between the Institute, the 





3. Results  
We screened peripheral blood samples of 78 sporadic MPM patients 
for germline BAP1 mutation. In these 78 patients there were 72 
males and 6 females (Supplementary Table II). The median age was 
61.2 years (SD ±6.1 years) at the date of diagnosis. The 
histopathology showed 69 tumors (88.5%) being epithelioid, 5 (6.4%) 
of sarcomatoid and 4 (5.1%) of the biphasic type. The stages at the 
time of diagnosis distributed as follows: 15 stage I (19.2%), 37 stage 
II (47.4%) and 26 stage III (33.3%). As positive control we sequenced 
the DNA of cell lines NCI-H2452 and NCI-H28 and confirmed the 
already reported missense mutation c.284C>A (p.A95D) in NCI-
H2452 [2, 13] and the 23-bp deletion at intron 6/exon7 junction 
(c.483-19_486del) in NCI-H28 [13]. 
The sequencing results of germline DNA showed wild-type BAP1 
sequence except for patient 76, where we found a known 
synonymous variant in exon 11 (rs71651686, c.1026C>T, Fig. 1), 
which does not result in a change of the encoded amino acid 
(p.Ser342=). This patient is still alive 24 months after diagnosis and 
has a tumor with epithelioid histotype (Supplementary Table II). He 
has a brother who died of leukemia. In all other samples we did not 
find any other alterations. 
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4. Discussion  
The screening of 78 MPM patients revealed absence of non-
synonymous germline BAP1 mutation. This observation is in contrast 
to the study of Testa et al.[14], where 2 individuals with non-
synonymous germline BAP1 mutation out of 26 sporadic MPM 
patients (8%) have been observed. The two patients carrying BAP1 
mutations had been previously treated for uveal melanoma (UM), 
while none of the remaining 24 individuals had UM in history. None of 
the 78 patients of our study reported UM history. However, our 
observations are consistent with the study of Yoshikawa et al.[13]. In 
that study no germline mutations were detected but the number of 
matching non tumoral samples available was very small (nine) to 
draw any definitive conclusion about the frequency of germline 
mutation in sporadic cancer. 
Altogether, 113 MPM patients were screened until to date for 
germline BAP1 mutation. Collectively, the prevalence of germline 
BAP1 mutations in sporadic MPM patients can be considered around 
1-2%. 
Similar screenings have been conducted for sporadic UM, where 
BAP1 has a predominant role in tumor predisposition syndrome. One 
study revealed that 2/66 (3%) unselected UM patients harbored a 
germline BAP1 mutation [21]. Harbour et al. found germline 
mutations in the BAP1 gene in 1/57 (1.75%) of UM patients [12] and 
Abdel-Rahman in 1/53 (1.9%) [17]. In another study [22], the 
prevalence of germline BAP1 mutation was 8% (4/50) in metastatic 
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UM versus 0% (0/50) in non-metastatic UM. Taking into account all 
these results, 8/276 of sporadic UM patients had BAP1 cancer 
syndrome, which corresponds to a prevalence of 2.9%, similar to 
what is observed in MPM patients. 
The prevalence of the silent mutation in the exon 11, which was 
detected in one patient (0.6%), is consistent with minor allele 
frequency observed in the Swiss normal population. Since 
synonymous mutations are able to cause changes in protein 
expression, conformation and function and are not as “silent” as 
supposed years ago [23], the relevance of this change for 
predisposition to tumor development remains to be explored. It is 
noteworthy that we could not find any nucleotide alterations at the 
position c.912, which correspond to the most frequent SNP, reported 
in the NCBI dbSNP database (rs201809705, c.912C>A, p.Ala304=) 
and again this is in line with the minor allele frequency observed in 
the Swiss cohort, indicating that wide variation exists, stressing the 
importance of control population. In previously BAP1 screening 
reports, SNPs were not mentioned, probably because of the 
supposed unimportant role of synonymous mutations. Only Aoude et 
al.[21] reported one synonymous variant in germline BAP1 
(rs28997577, on the same exon 24 nucleotides away from the 
synonymous variant rs71651686) out of 66 UM patients.  
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5. Conclusion  
Taken together, the screenings performed up to the present suggest 
a minor role of germline BAP1 mutation in the pathogenesis of 
sporadic MPM. Nevertheless, if a patient reports asbestos exposure 
and UM in the past, or if there is a familial predisposition syndrome, 
germline BAP1 testing must be considered. 
 11 
6. Acknowledgements 
This work was supported by the Sassella Stiftung. We thank Ubiratan 
Moura for his skilful help with genomic DNA extraction. We are 
grateful for access to exome sequence data from the CoLaus cohort, 
which was sequenced as part of a partnership between the 
Wellcome Trust Sanger Institute, the CoLaus principal investigators 
and the Quantitative Sciences dept. of GlaxoSmithKline. We thank 




Conflict of interest statement 




1. Bertino P, Carbone M, Pass H. Chemotherapy of malignant 
pleural mesothelioma. Expert Opin Pharmacother 2009;10: 
99-107. 
2. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, 
Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite 
R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. 
The nuclear deubiquitinase BAP1 is commonly inactivated by 
somatic mutations and 3p21.1 losses in malignant pleural 
mesothelioma. Nat Genet 2011;43: 668-672. 
3. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, 
Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, 
Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, 
Barlev N, Berger SL, Prendergast GC, Rauscher FJ, 3rd. 
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 
RING finger and enhances BRCA1-mediated cell growth 
suppression. Oncogene 1998;16: 1097-1112. 
4. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, 
Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a 
tumor suppressor that requires deubiquitinating activity and 
nuclear localization. Cancer Res 2008;68: 6953-6962. 
5. Mallery DL, Vandenberg CJ, Hiom K. Activation of the E3 
ligase function of the BRCA1/BARD1 complex by polyubiquitin 
chains. EMBO J 2002;21: 6755-6762. 
6. Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, 
Miroslaw L, Poser I, Lawo S, Grabner H, Kozak K, Wagner J, 
Surendranath V, Richter C, Bowen W, Jackson AL, 
Habermann B, Hyman AA, Buchholz F. Genome-scale RNAi 
profiling of cell division in human tissue culture cells. Nat Cell 
Biol 2007;9: 1401-1412. 
7. Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, 
Hart GW, Rauscher FJ, 3rd, Drobetsky E, Milot E, Shi Y, Affar 
el B. The ubiquitin carboxyl hydrolase BAP1 forms a ternary 
complex with YY1 and HCF-1 and is a critical regulator of 
gene expression. Mol Cell Biol 2010;30: 5071-5085. 
8. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta 
A. The deubiquitinating enzyme BAP1 regulates cell growth 
via interaction with HCF-1. J Biol Chem 2009;284: 34179-
34188. 
9. Murali R, Wiesner T, Scolyer RA. Tumours associated with 
BAP1 mutations. Pathology 2013;45: 116-126. 
 13 
10. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. 
BAP1 and cancer. Nat Rev Cancer 2013;13: 153-159. 
11. Knudson AG, Jr. Mutation and cancer: statistical study of 
retinoblastoma. Proc Natl Acad Sci U S A 1971;68: 820-823. 
12. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, 
Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. 
Frequent mutation of BAP1 in metastasizing uveal 
melanomas. Science 2010;330: 1410-1413. 
13. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, 
Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, 
Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-
Tamaoki T. Frequent inactivation of the BAP1 gene in 
epithelioid-type malignant mesothelioma. Cancer Sci 
2012;103: 868-874. 
14. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, 
Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, 
Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang 
H, Carbone M. Germline BAP1 mutations predispose to 
malignant mesothelioma. Nat Genet 2011;43:1022-1025 
15. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, 
Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, 
Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, 
Yang H. BAP1 cancer syndrome: malignant mesothelioma, 
uveal and cutaneous melanoma, and MBAITs. J Transl Med 
2012;10: 179. 
16. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz 
P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, 
Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson 
D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, 
Speicher MR. Germline mutations in BAP1 predispose to 
melanocytic tumors. Nat Genet 2011;43: 1018-1021. 
17. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, 
Christopher BN, Boru G, Hovland P, Davidorf FH. Germline 
BAP1 mutation predisposes to uveal melanoma, lung 
adenocarcinoma, meningioma, and other cancers. J Med 
Genet 2011;48: 856-859. 
18. Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier 
V, Dubois-d'Enghien C, Richaudeau B, Renaudin X, Sellers J, 
Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal 
V, Sinilnikova OM, Andrieu N, Manie E, de Pauw A, Gesta P, 
Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, 
Cabaret O, Delattre O, Richard S, Caron O, Benfodda M, Hu 
HH, Soufir N, Bressac-de Paillerets B, Stoppa-Lyonnet D, 
Stern MH. Germline BAP1 mutations predispose to renal cell 
carcinomas. Am J Hum Genet 2013;92: 974-980. 
 14 
19. Rusch VW. A proposed new international TNM staging system 
for malignant pleural mesothelioma from the International 
Mesothelioma Interest Group. Lung Cancer 1996;14: 1-12. 
20. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz 
D, Paccaud F, Preisig M, Song KS, Yuan X, Danoff TM, 
Stirnadel HA, Waterworth D, Mooser V, Waeber G, 
Vollenweider P. The CoLaus study: a population-based study 
to investigate the epidemiology and genetic determinants of 
cardiovascular risk factors and metabolic syndrome. BMC 
Cardiovasc Disord 2008;8: 6. 
21. Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. 
Prevalence of germline BAP1 mutation in a population-based 
sample of uveal melanoma cases. Pigment Cell Melanoma 
Res 2013;26: 278-279. 
22. Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, 
DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. Germline 
BAP1 inactivation is preferentially associated with metastatic 
ocular melanoma and cutaneous-ocular melanoma families. 
PLoS One 2012;7: e35295. 
23. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution 





8. Legends to the figures 
Figure 1.  
Electropherogram of DNA alteration in exon 11 of BAP1 gene in 
patient 76. The synonymous variation c.1026C>T does not lead to a 
change in the encoded amino acid (p.Ser342=) It is reported on 
Ensembl and dbSNP database (rs71651686).  
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